Adjuvanted Fusion Protein Vaccine Induces Durable Immunity to Onchocerca volvulus in Mice and Non-Human Primates
Authors:
- Nathan M. RyanNRNathan M. Ryan
- Jessica A. HessJHJessica A. Hess
- Erica J. RobertsonERErica J. Robertson
- Nancy TricocheNTNancy Tricoche
- Cheri TurnerCTCheri Turner
- Jenn DavisJDJenn Davis
- Nikolai PetrovskyNPNikolai Petrovsky
- Melissa FergusonMFMelissa Ferguson
- William J. RinaldiWRWilliam J. Rinaldi
- Valerie M. WongVWValerie M. Wong
- Ayako ShimadaASAyako Shimada
- Bin ZhanBin Zhan
Open Access
Abstract
Onchocerciasis remains a debilitating neglected tropical disease. Due to the many challenges of current control methods, an effective vaccine against the causative agent Onchocerca volvulus is urgently needed. Mice and cynomolgus macaque non-human primates (NHPs) were immunized with a vaccine consisting of a fusion of two O. volvulus protein antigens, Ov-103 and Ov-RAL-2 (Ov-FUS-1), and three different adjuvants: Advax-CpG, alum, and AlT4. All vaccine formulations induced high antigen-specific IgG titers in both mice and NHPs. Challenging mice with O. volvulus L3 contained within subcutaneous diffusion chambers demonstrated that Ov-FUS-1/Advax-CpG-immunized animals developed protective immunity, durable for at least 11 weeks. Passive transfer of sera, collected at several time points, from both mice and NHPs immunized with Ov-FUS-1/Advax-CpG transferred protection to naïve mice. These results demonstrate that Ov-FUS-1 with the adjuvant Advax-CpG induces durable protective immunity against O. volvulus in mice and NHPs that is mediated by vaccine-induced humoral factors.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R01 AI078314, 75N93019C00028, HHS-N272201400053C, HHS-N272200800039C, U01-AI061142)
This publication has 72 references indexed in Scilit:
- Vaccine Adjuvants: Mode of ActionFrontiers in Immunology, 2013
- Mechanism of Immunopotentiation and Safety of Aluminum AdjuvantsFrontiers in Immunology, 2013
- Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvantVaccine, 2012
- CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaquesVaccine, 2004
- A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemiaBlood, 2004
- Immunoglobulin E and Eosinophil-Dependent Protective Immunity to LarvalOnchocerca volvulusin Mice Immunized with Irradiated LarvaeInfection and Immunity, 2004
- Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloidInternational Immunology, 2003
- Identification and characterization of an Onchocerca volvulus cDNA clone encoding a microfilarial surface-associated antigenMolecular and Biochemical Parasitology, 1992
- Impact of Mass Treatment of Onchocerciasis with Ivermectin on the Transmission of InfectionScience, 1990
- Regulation of antibody isotype secretion by subsets of antigen-specific helper T cellsNature, 1988